Compare RWT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | RLMD |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | 351 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 574.0M | 524.9M |
| IPO Year | N/A | 2012 |
| Metric | RWT | RLMD |
|---|---|---|
| Price | $4.74 | $4.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $6.82 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $22.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $4.19 | $0.55 |
| 52 Week High | $6.97 | $8.00 |
| Indicator | RWT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 41.64 |
| Support Level | $4.44 | $4.06 |
| Resistance Level | $5.36 | $7.28 |
| Average True Range (ATR) | 0.16 | 0.33 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 17.61 | 71.72 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.